Unfortunately, and although SST analogs are widely used for the control of several types of tumors (e.g., pituitary and neuroendocrine tumors [41, 43]), clinical trials in humans with breast tumors using SST analogs have been inconclusive and unsuccessful [8, 44]. The gene discussed is SST; the disease is neuroendocrine neoplasm.